Byrne Asset Management LLC Cassava Sciences Inc Transaction History

Byrne Asset Management LLC

$116 Million
Q2 2024

A detailed history of Byrne Asset Management LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Byrne Asset Management LLC holds 3,535 shares of SAVA stock, worth $92,086. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,535

Previous 3,620 2.35%

Holding current value

$92,086

Previous $73,000 41.1%

% of portfolio

0.04%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$12.35 - $26.11 $1,049 - $2,219	-85 Reduced 2.35%	3,535 $43,000
Q1 2024 Apr 22, 2024	BUY	$18.44 - $26.41 $4,978 - $7,130	270 Added 8.06%	3,620 $73,000
Q4 2023 Jan 29, 2024	BUY	$12.64 - $30.11 $10,491 - $24,991	830 Added 32.94%	3,350 $75,000
Q3 2023 Oct 31, 2023	BUY	$16.64 - $25.32 $3,827 - $5,823	230 Added 10.04%	2,520 $41,000
Q2 2023 Jul 21, 2023	BUY	$21.59 - $27.88 $7,448 - $9,618	345 Added 17.74%	2,290 $56,000
Q1 2023 Apr 17, 2023	SELL	$23.46 - $36.44 $17,571 - $27,293	-749 Reduced 27.8%	1,945 $46,000
Q4 2022 Jan 30, 2023	BUY	$27.82 - $44.16 $14,216 - $22,565	511 Added 23.41%	2,694 $79,000
Q3 2022 Oct 19, 2022	SELL	$16.33 - $51.06 $2,090 - $6,535	-128 Reduced 5.54%	2,183 $91,000
Q2 2022 Jul 20, 2022	SELL	$17.22 - $38.47 $21,180 - $47,318	-1,230 Reduced 34.74%	2,311 $73,000
Q1 2022 Apr 05, 2022	BUY	$32.6 - $53.05 $45,085 - $73,368	1,383 Added 64.09%	3,541 $132,000
Q4 2021 Feb 22, 2022	BUY	$36.77 - $90.91 $79,349 - $196,183	2,158 New	2,158 $94,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.04B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.

Account

Byrne Asset Management LLC Cassava Sciences Inc Transaction History